Citadel Advisors’s Generation Bio GBIO Stock Holding History

Citadel Advisors’s Portfolio GBIO Stock Details GBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-70	Closed	-$284	–	13413
2025 Q1	$284	Buy	70 +60	+600%	+$422	﹤0.01%	14293
2024 Q4	$106	Buy	+10	New	+$178	﹤0.01%	14380
2024 Q3	–	Sell	-20	Closed	-$564	–	14565
2024 Q2	$564	Buy	+20	New	+$650	﹤0.01%	13961
2023 Q4	–	Sell	-460	Closed	-$17.4K	–	14631
2023 Q3	$17.4K	Sell	460 -80	-15%	-$3.79K	﹤0.01%	12728
2023 Q2	$29.7K	Buy	540 +310	+135%	+$14.2K	﹤0.01%	12363
2023 Q1	$9.89K	Buy	230 +130	+130%	+$6.29K	﹤0.01%	13556
2022 Q4	$3.93K	Buy	+100	New	+$5.25K	﹤0.01%	14157
2021 Q2	–	Sell	-1,350	Closed	-$384K	–	13935
2021 Q1	$384K	Buy	+1,350	New	+$432K	﹤0.01%	10281

Other funds holding GBIO

ACM

Accent Capital Management Centerville, Ohio $206M AUM 29.56% 1-Year Est. Return

Citadel Advisors's GBIO Position: Q1 2026 in Review

Citadel Advisors sold out of Generation Bio (GBIO) in Q1 2026, closing a stake of 47,245 shares — an estimated $268K sold.

Citadel Advisors first reported a position in GBIO in Q2 2020 and held it in 19 quarters. The position peaked at $11.4M in Q2 2020. 2 funds tracked by Wall St. Rank hold GBIO as of Q1 2026.

Citadel Advisors reported no remaining Generation Bio position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 47,245 Generation Bio shares in Q1 2026, an estimated $268K.
Citadel Advisors first reported a position in Generation Bio in Q2 2020 and held it in 19 quarters.
Citadel Advisors's Generation Bio position peaked at $11.4M in Q2 2020.
2 funds tracked by Wall St. Rank held Generation Bio as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.